551 related articles for article (PubMed ID: 30995737)
1. Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder.
Barone R; Rizzo R; Tabbì G; Malaguarnera M; Frye RE; Bastin J
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30995737
[TBL] [Abstract][Full Text] [Related]
2. Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases.
Khuchua Z; Glukhov AI; Strauss AW; Javadov S
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400386
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
4. Palmitoylethanolamide counteracts autistic-like behaviours in BTBR T+tf/J mice: Contribution of central and peripheral mechanisms.
Cristiano C; Pirozzi C; Coretti L; Cavaliere G; Lama A; Russo R; Lembo F; Mollica MP; Meli R; Calignano A; Mattace Raso G
Brain Behav Immun; 2018 Nov; 74():166-175. PubMed ID: 30193877
[TBL] [Abstract][Full Text] [Related]
5. Next generation sequencing of RNA reveals novel targets of resveratrol with possible implications for Canavan disease.
Dembic M; Andersen HS; Bastin J; Doktor TK; Corydon TJ; Sass JO; Lopes Costa A; Djouadi F; Andresen BS
Mol Genet Metab; 2019 Jan; 126(1):64-76. PubMed ID: 30446350
[TBL] [Abstract][Full Text] [Related]
6. Regulation of energy metabolism by long-chain fatty acids.
Nakamura MT; Yudell BE; Loor JJ
Prog Lipid Res; 2014 Jan; 53():124-44. PubMed ID: 24362249
[TBL] [Abstract][Full Text] [Related]
7. PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8
Chowdhury PS; Chamoto K; Kumar A; Honjo T
Cancer Immunol Res; 2018 Nov; 6(11):1375-1387. PubMed ID: 30143538
[TBL] [Abstract][Full Text] [Related]
8. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts.
Bastin J; Lopes-Costa A; Djouadi F
Hum Mol Genet; 2011 May; 20(10):2048-57. PubMed ID: 21378393
[TBL] [Abstract][Full Text] [Related]
9. Biology and therapeutic applications of peroxisome proliferator- activated receptors.
Menendez-Gutierrez MP; Roszer T; Ricote M
Curr Top Med Chem; 2012; 12(6):548-84. PubMed ID: 22242855
[TBL] [Abstract][Full Text] [Related]
10. Enhancing fatty acid oxidation negatively regulates PPARs signaling in the heart.
Liu Z; Ding J; McMillen TS; Villet O; Tian R; Shao D
J Mol Cell Cardiol; 2020 Sep; 146():1-11. PubMed ID: 32592696
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptors in cardiac energy metabolism and cardiovascular disease.
Ajith TA; Jayakumar TG
Clin Exp Pharmacol Physiol; 2016 Jul; 43(7):649-58. PubMed ID: 27115677
[TBL] [Abstract][Full Text] [Related]
12. Novel role of peroxisome proliferator activated receptor-α in valproic acid rat model of autism: Mechanistic study of risperidone and metformin monotherapy versus combination.
Elnahas EM; Abuelezz SA; Mohamad MI; Nabil MM; Abdelraouf SM; Bahaa N; Hassan GAM; Aboul-Fotouh S
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jun; 116():110522. PubMed ID: 35131336
[TBL] [Abstract][Full Text] [Related]
13. Stilbenes and resveratrol metabolites improve mitochondrial fatty acid oxidation defects in human fibroblasts.
Aires V; Delmas D; Le Bachelier C; Latruffe N; Schlemmer D; Benoist JF; Djouadi F; Bastin J
Orphanet J Rare Dis; 2014 Jun; 9():79. PubMed ID: 24898617
[TBL] [Abstract][Full Text] [Related]
14. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
Derosa G; Sahebkar A; Maffioli P
J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
[TBL] [Abstract][Full Text] [Related]
15. Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence.
Colizzi M; Bortoletto R; Costa R; Zoccante L
Nutrients; 2021 Apr; 13(4):. PubMed ID: 33919499
[TBL] [Abstract][Full Text] [Related]
16. Pivotal Roles of Peroxisome Proliferator-Activated Receptors (PPARs) and Their Signal Cascade for Cellular and Whole-Body Energy Homeostasis.
Lamichane S; Dahal Lamichane B; Kwon SM
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29565812
[TBL] [Abstract][Full Text] [Related]
17. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
Gervois P; Fruchart JC; Staels B
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptors as attractive antiobesity targets.
Zhang F; Lavan B; Gregoire FM
Drug News Perspect; 2004 Dec; 17(10):661-9. PubMed ID: 15696231
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha as a Novel Target for Bipolar Disorder and Other Neuropsychiatric Disorders.
Nierenberg AA; Ghaznavi SA; Sande Mathias I; Ellard KK; Janos JA; Sylvia LG
Biol Psychiatry; 2018 May; 83(9):761-769. PubMed ID: 29502862
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.
Wagner N; Wagner KD
Cells; 2022 Aug; 11(15):. PubMed ID: 35954274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
